Stifel has revised its price outlook for Idexx Laboratories (IDXX, Financial), decreasing the target from $450 to $420. This adjustment follows an in-depth survey evaluating the latest innovations from leading companies within the Animal Health sector. Despite the adjustment, Stifel maintains its Hold rating on Idexx shares, reflecting a cautious stance amid ongoing market developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for IDEXX Laboratories Inc (IDXX, Financial) is $508.04 with a high estimate of $566.00 and a low estimate of $389.50. The average target implies an upside of 29.95% from the current price of $390.94. More detailed estimate data can be found on the IDEXX Laboratories Inc (IDXX) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, IDEXX Laboratories Inc's (IDXX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for IDEXX Laboratories Inc (IDXX, Financial) in one year is $568.23, suggesting a upside of 45.35% from the current price of $390.94. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the IDEXX Laboratories Inc (IDXX) Summary page.
